Sign in

CholestasisDoc

@cholestasisdoc.bsky.social
237 followers 49 following 7 posts

Hospital doctor, with interests in liver medicine, transplantation and inflammatory bowel disease. Combat sports’ enthusiast, and occasional stand up comic.

PostsRepliesMedia
Reposted by CholestasisDoc
Ben Mullish @bhmullish.bsky.social · 11/09/2025
Honoured to speak on #FMT #LBPs at the #EHMSG meeting today in session with Nicolas Benech and Jens Walter. Thanks to Gianluca Ianiro for organising, and for even getting a @nobelprize.bsky.social winner for Physics to speak to us, Giorgio Parisi! @imperialmdr.bsky.social #microbiomeclinicians
282
Reposted by CholestasisDoc
The Lancet @thelancet.com · 15/01/2025
🆕 Global Commission proposes overhaul of obesity diagnosis – going beyond BMI to define when obesity is a disease. Find out more: hubs.li/Q030v_j_0
Infographic panel for the Lancet Diabetes & Endocrinology Commission on diagnosing clinical obesity.
23516
Reposted by CholestasisDoc
Rob Brierley @robbrierley.bsky.social · 15/01/2025
New research - Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial www.thelancet.com/journals/lan... #GastroSky #OncSky #MedSky @oncoalert.bsky.social
095
Reposted by CholestasisDoc
Ben Mullish @bhmullish.bsky.social · 07/01/2025
Pleased that #FARGO - a randomised, multicentre, placebo-controlled phase IIa trial of #FMT to treat #PSC - is running and recruiting. Have a look at the protocol paper out now in #BMJOpen: doi.org/10.1136/bmjo... @pscsupport.bsky.social @cholestasisdoc.bsky.social
doi.org
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial
Introduction Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven...
12310
CholestasisDoc @cholestasisdoc.bsky.social · 07/01/2025
New from us: our trial protocol for faecal microbiota transplantation to treat people living with PSC and IBD. Actively recruiting! @bhmullish.bsky.social @nabilquraishi.bsky.social @alanmcn1.bsky.social @pscsupport.bsky.social bmjopen.bmj.com/content/bmjo...
bmjopen.bmj.com
072
CholestasisDoc @cholestasisdoc.bsky.social · 26/12/2024
Agree that mRNA vaccine technology needs deeper evaluation. @fda.gov should provide further details in due course. www.bmj.com/content/387/...
bmj.com
FDA pauses all infant RSV vaccine trials after rise in severe illnesses
The US Food and Drug Administration (FDA) has put on hold all respiratory syncytial virus (RSV) vaccine trials involving infants (aged under 2 years) or RSV naive children aged 2-5 years, after a tria...
000
CholestasisDoc @cholestasisdoc.bsky.social · 14/12/2024
New work from us: Oral vancomycin is associated with attenuation in IBD activity in people with PSC. We also studied changes in gut microbiome profile, and key transcriptomic and metabolomic features. academic.oup.com/ecco-jcc/adv...
academic.oup.com
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures
AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV
062
Reposted by CholestasisDoc
Ben Mullish @bhmullish.bsky.social · 14/12/2024
Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky
academic.oup.com
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures
AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV
0257